Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for AN4005 (PD-L1 Inhibitor) in Cancer, Advanced Tumors. The expected timing is based on the latest available company guidance and may change.
08/14/26:- AN4005 monotherapy was de-prioritized. Expansion-cohort clinical data is expected at the 2026 SITC meeting.
Verification
Confirm timing and program details against the company announcement or filing.